{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:24:48Z","timestamp":1787232288101,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,20]]},"DOI":"10.7759\/cureus.114850","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:30:30Z","timestamp":1787229030000},"source":"Crossref","is-referenced-by-count":0,"title":["Candidate MicroRNA Regulatory Axes in Melanoma CD8+ T Cell Exhaustion: A Network-Based In Silico Stratification"],"prefix":"10.7759","author":[{"given":"Muhammad Zain U","family":"Javed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert C","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al.. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015, 372:2521-2532. 10.1056\/NEJMoa1503093","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert C","year":"2015","unstructured":"Robert C, Long GV, Brady B, et al.. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015, 372:320-330. 10.1056\/NEJMoa1412082","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok JD","year":"2022","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al.. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol. 2022, 40:127-137. 10.1200\/JCO.21.02229","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma P","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017, 168:707-723. 10.1016\/j.cell.2017.01.017","journal-title":"Cell"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry EJ","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015, 15:486-499. 10.1038\/nri3862","journal-title":"Nat Rev Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00574-3","article-title":"CD8(+) T cell differentiation and dysfunction in cancer","volume":"22","author":"Philip M","year":"2022","unstructured":"Philip M, Schietinger A. CD8(+) T cell differentiation and dysfunction in cancer. Nat Rev Immunol. 2022, 22:209-223. 10.1038\/s41577-021-00574-3","journal-title":"Nat Rev Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1324-y","article-title":"TOX is a critical regulator of tumour-specific T cell differentiation","volume":"571","author":"Scott AC","year":"2019","unstructured":"Scott AC, D\u00fcndar F, Zumbo P, et al.. TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019, 571:270-274. 10.1038\/s41586-019-1324-y","journal-title":"Nature"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller BC","year":"2019","unstructured":"Miller BC, Sen DR, Al Abosy R, et al.. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019, 20:326-336. 10.1038\/s41590-019-0312-6","journal-title":"Nat Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-96-9428-0_18","article-title":"Circular RNAs and cancers","volume":"1485","author":"Heidari MM","year":"2025","unstructured":"Heidari MM, Moeinfar MS, Rafiyan M, et al.. Circular RNAs and cancers. Adv Exp Med Biol. 2025, 1485:273-327. 10.1007\/978-981-96-9428-0_18","journal-title":"Adv Exp Med Biol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2010.09.009","article-title":"MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development","volume":"33","author":"O'Connell RM","year":"2010","unstructured":"O'Connell RM, Kahn D, Gibson WS, et al.. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity. 2010, 33:607-619. 10.1016\/j.immuni.2010.09.009","journal-title":"Immunity"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0605298103","article-title":"NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses","volume":"103","author":"Taganov KD","year":"2006","unstructured":"Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A. 2006, 103:12481-12486. 10.1073\/pnas.0605298103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1315","article-title":"Integrative analysis of competing endogenous RNA network focusing on long noncoding RNA associated with progression of cutaneous melanoma","volume":"7","author":"Xu S","year":"2018","unstructured":"Xu S, Sui J, Yang S, Liu Y, Wang Y, Liang G. Integrative analysis of competing endogenous RNA network focusing on long noncoding RNA associated with progression of cutaneous melanoma. Cancer Med. 2018, 7:1019-1029. 10.1002\/cam4.1315","journal-title":"Cancer Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07302-5","article-title":"Reconstruction of lncRNA-miRNA-mRNA network based on competitive endogenous RNA reveals functional lncRNAs in skin cutaneous melanoma","volume":"20","author":"Zhu J","year":"2020","unstructured":"Zhu J, Deng J, Zhang L, et al.. Reconstruction of lncRNA-miRNA-mRNA network based on competitive endogenous RNA reveals functional lncRNAs in skin cutaneous melanoma. BMC Cancer. 2020, 20:927. 10.1186\/s12885-020-07302-5","journal-title":"BMC Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami E","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, et al.. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2:401-404. 10.1158\/2159-8290.CD-12-0095","journal-title":"Cancer Discov"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo W","year":"2016","unstructured":"Hugo W, Zaretsky JM, Sun L, et al.. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016, 165:35-44. 10.1016\/j.cell.2016.02.065","journal-title":"Cell"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkab1079","article-title":"miRTarBase update 2022: an informative resource for experimentally validated miRNA-target interactions","volume":"50","author":"Huang HY","year":"2022","unstructured":"Huang HY, Lin YC, Cui S, et al.. miRTarBase update 2022: an informative resource for experimentally validated miRNA-target interactions. Nucleic Acids Res. 2022, 50:D222-D230. 10.1093\/nar\/gkab1079","journal-title":"Nucleic Acids Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz757","article-title":"miRDB: an online database for prediction of functional microRNA targets","volume":"48","author":"Chen Y","year":"2020","unstructured":"Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res. 2020, 48:D127-D131. 10.1093\/nar\/gkz757","journal-title":"Nucleic Acids Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0654-5","article-title":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","volume":"25","author":"Liu D","year":"2019","unstructured":"Liu D, Schilling B, Liu D, et al.. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019, 25:1916-1927. 10.1038\/s41591-019-0654-5","journal-title":"Nat Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian A","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, et al.. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005, 102:15545-15550. 10.1073\/pnas.0506580102","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9971","article-title":"Systematic pan-cancer analysis of tumour purity","volume":"6","author":"Aran D","year":"2015","unstructured":"Aran D, Sirota M, Butte AJ. Systematic pan-cancer analysis of tumour purity. Nat Commun. 2015, 6:8971. 10.1038\/ncomms9971","journal-title":"Nat Commun"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1070-5","article-title":"Estimating the\u00a0population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht E","year":"2016","unstructured":"Becht E, Giraldo NA, Lacroix L, et al.. Estimating the\u00a0population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016, 17:218. 10.1186\/s13059-016-1070-5","journal-title":"Genome Biol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon A","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015, 1:417-425. 10.1016\/j.cels.2015.12.004","journal-title":"Cell Syst"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman M","year":"2018","unstructured":"Sade-Feldman M, Yizhak K, Bjorgaard SL, et al.. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell. 2018, 175:998-1013.e20. 10.1016\/j.cell.2018.10.038","journal-title":"Cell"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1126\/science.aae0491","article-title":"The epigenetic landscape of T cell exhaustion","volume":"354","author":"Sen DR","year":"2016","unstructured":"Sen DR, Kaminski J, Barnitz RA, et al.. The epigenetic landscape of T cell exhaustion. Science. 2016, 354:1165-1169. 10.1126\/science.aae0491","journal-title":"Science"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10731","article-title":"miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion","volume":"7","author":"Li Q","year":"2016","unstructured":"Li Q, Johnston N, Zheng X, Wang H, Zhang X, Gao D, Min W. miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion. Oncotarget. 2016, 7:53735-53750. 10.18632\/oncotarget.10731","journal-title":"Oncotarget"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23044-9","article-title":"Antigen-driven EGR2 expression is required for exhausted CD8(+) T cell stability and maintenance","volume":"12","author":"Wagle MV","year":"2021","unstructured":"Wagle MV, Vervoort SJ, Kelly MJ, et al.. Antigen-driven EGR2 expression is required for exhausted CD8(+) T cell stability and maintenance. Nat Commun. 2021, 12:2782. 10.1038\/s41467-021-23044-9","journal-title":"Nat Commun"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09882-8","article-title":"miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8(+) T cell fate","volume":"10","author":"Ji Y","year":"2019","unstructured":"Ji Y, Fioravanti J, Zhu W, et al.. miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8(+) T cell fate. Nat Commun. 2019, 10:2157. 10.1038\/s41467-019-09882-8","journal-title":"Nat Commun"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002533","article-title":"FOXO3 regulates CD8 T cell memory by T cell-intrinsic mechanisms","volume":"8","author":"Sullivan JA","year":"2012","unstructured":"Sullivan JA, Kim EH, Plisch EH, Peng SL, Suresh M. FOXO3 regulates CD8 T cell memory by T cell-intrinsic mechanisms. PLoS Pathog. 2012, 8:e1002533. 10.1371\/journal.ppat.1002533","journal-title":"PLoS Pathog"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2014.03.045","article-title":"Assessing the ceRNA hypothesis with quantitative measurements of miRNA and target abundance","volume":"54","author":"Denzler R","year":"2014","unstructured":"Denzler R, Agarwal V, Stefano J, Bartel DP, Stoffel M. Assessing the ceRNA hypothesis with quantitative measurements of miRNA and target abundance. Mol Cell. 2014, 54:766-776. 10.1016\/j.molcel.2014.03.045","journal-title":"Mol Cell"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27651-4","article-title":"Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association","volume":"13","author":"Wu CC","year":"2022","unstructured":"Wu CC, Wang YA, Livingston JA, Zhang J, Futreal PA. Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association. Nat Commun. 2022, 13:42. 10.1038\/s41467-021-27651-4","journal-title":"Nat Commun"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/500425-candidate-microrna-regulatory-axes-in-melanoma-cd8-t-cell-exhaustion-a-network-based-in-silico-stratification","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:30:31Z","timestamp":1787229031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/500425-candidate-microrna-regulatory-axes-in-melanoma-cd8-t-cell-exhaustion-a-network-based-in-silico-stratification"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.114850","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,20]]}}}